Files

2026_Constantinescu_LM_145_32-38.pdf
  • Open Access
  • Adobe PDF
  • 1.59 MB
Download

Details

Authors
Show more
Abstract
(en) [Innovations in endocrinology in 2025] In 2025, the field of endocrinology witnessed a deeper understanding of the cardiovascular and muscular effects of incretin-based therapies. The SOUL trial demonstrated that oral semaglutide significantly reduces the risk of major cardiovascular events. The SURPASS CVOT study showed the cardiovascular non-inferiority of tirzepatide (a dual GIP and GLP-1 receptor agonist) compared to dulaglutide, while also proving its superiority in terms of weight reduction, glycemic control, and overall improvement of metabolic risk factors. In parallel, the SEMALEAN (semaglutide 2.4 mg in obesity) and SURPASS-3 MRI (tirzepatide in type 2 diabetes) trials demonstrated, respectively, a preservation—or even an improvement—of muscle strength and a reduction in myosteatosis during treatment. These findings suggest that these agents enhance muscle function and quality despite weight loss. However, some patients develop sarcopenia under treatment, warranting individualized screening, particularly in older adults. On the other hand, a less invasive approach has been proposed for managing arginine vasopressin deficiency (central diabetes insipidus) and aldosterone-producing adrenal adenomas. From a diagnostic standpoint, a new clinical score and baseline copeptin measurement have been developed for arginine vasopressin deficiency, which may simplify the patient pathway by avoiding dynamic inpatient testing in most cases. Finally, the FABULAS trial established endoscopic ultrasound-guided transgastric radiofrequency ablation as a minimally invasive alternative to surgery for treating left-sided aldosterone-secreting adrenal adenomas.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Constantinescu, S., Lurquin, F., Orioli, L., Loumaye, A., Furnica, R.-M., Deprez, P., Hermans, M., Thissen, J.-P., & Alexopoulou, O. (2026). Innovations 2025 en Endocrinologie et Nutrition. Louvain médical, 145(2), 32-38. https://hdl.handle.net/2078.5/276568 (Original work published 2026)